dromlakhani Indicate chemotherapy for unresectable pheochromocytoma and paraganglioma
STEP 1 — Gather Information
Collect: unresectability status (surgical/technical), progression rate (rapid vs slow based on tumor growth or biomarker rise), nuclear imaging results (123I-MIBG scintigraphy, somatostatin receptor PET/CT), feasibility of radionuclide therapy (availability, contraindications), baseline labs (CBC, LFT, renal function), catecholamine levels, symptoms, ECOG performance status.
Action: Proceed to assess resectability.
STEP 2 — Rule In / Rule Out
Is the PPGL unresectable (locally advanced, metastatic, or medically inoperable)?
- If resectable → recommend surgical resection (not chemotherapy).
- If unresectable → proceed to evaluate progression rate and radionuclide feasibility.
STEP 3 — Classify or Stratify
Is disease progression rapid or is radionuclide therapy not applicable (contraindicated, unavailable, or patient refuses)?
- If yes → recommend CVD chemotherapy as first-line systemic treatment.
- If no (slow progression and radionuclide therapy feasible) → proceed to assess nuclear imaging status.
STEP 4 — Decide
Based on nuclear imaging:
- If positive (123I-MIBG or somatostatin receptor avid uptake) → choose between CVD chemotherapy and radionuclide therapy: favor CVD chemotherapy if progression is rapid or radionuclide feasibility low; favor radionuclide therapy if progression is slow and therapy feasible.
- If negative → recommend CVD chemotherapy (preferred when nuclear imaging negative).
Action: Initiate selected systemic therapy with appropriate pretreatment (α‑blockade, hydration) and monitoring.
Clinical Guardrails / Mimics / Pitfalls
Do not use CVD chemotherapy in patients with severe bone marrow suppression (ANC <1.0×10⁹/L, platelets <50×10⁹/L), uncontrolled hypertension despite adequate α‑blockade, active infection, or pregnancy. Avoid in patients with severe hepatic or renal dysfunction (ALT/AST >3×ULN, creatinine clearance <30 mL/min). Monitor for hypertensive crisis due to tumor lysis during early cycles; have phentolamine ready. Do not substitute CVD chemotherapy for observation in indolent disease without progression.
Concrete Clinical Example
A 60‑year‑old with unresectable retroperitoneal PPGL, rising normetanephrine (×3 ULN in 3 months), lung metastases, 123I‑MBG scintigraphy negative, ECOG 1, normal CBC and LFTs. Disease deemed rapidly progressive; radionuclide therapy not considered due to negative imaging.
Action: Start CVD chemotherapy (cyclophosphamide 750 mg/m² day 1, vincristine 1.4 mg/m² day 1, dacarbazine 600 mg/m² days 1‑2) every 21 days.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165